
|Articles|December 10, 2014
Closing gaps in psoriasis research
Author(s)Lisette Hilton
Listen
0:00 / 0:00
Key Takeaways
- Further research is needed to understand psoriasis prevalence, natural history, and the molecular functions of susceptibility genes to identify new therapeutic targets.
- Environmental factors' roles in psoriasis development and the relationship between cardiometabolic disease and psoriasis require further investigation.
A report published in January 2014 identified several gaps in psoriasis research and recommended research targets to address these gaps.
Advertisement
Dr. Feldman and colleagues reported in January 2014 that gaps remain in psoriasis research. Based on their study, the authors recommend:
- Basic science and clinical research studies to determine the true prevalence and natural history of psoriasis.
- Molecular studies in patients with psoriasis and psoriatic arthritis, looking at the function of psoriasis susceptibility genes and to identify new therapeutic targets.
- Studies examining environmental factors' roles in psoriasis development of psoriasis.
- Investigations centered on the relationship between cardiometabolic disease and psoriasis.
- Studies focused on the potential impact of adjunctive therapies, including psychological interventions.
- And studies to pinpoint disease severity biomarkers and treatment response to improve patient therapy.
Source: Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014 Jan;70(1):146-67. doi: 10.1016/j.jaad.2013.08.042. Epub 2013 Oct 11. Review.
READ MORE:
Advertisement
Related to this article

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

Doral Fredericks, PharmD, MBA, discusses how life stages, mental health, and reproductive concerns can shape dermatologic care for women.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Implements Updated iPLEDGE REMS Requirements for Isotretinoin
2
Monitoring and Treatment Selection for Oral TYK2 Inhibitors in Psoriasis
3
CIndU Patient Demographics: Disease Duration, Diagnostic Delay, and Quality of Life
4
Bioelements and Celluma Collaborate on LED Facial Treatments
5

